The safe handling of chemotherapy drugs in low- and middle-income countries: An overview of practices.
Safe handling practices
chemotherapy
cytotoxic drugs
low- and middle-income countries
oncology
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
25
2
2021
medline:
10
2
2022
entrez:
24
2
2021
Statut:
ppublish
Résumé
The rising burden of cancer in low- and middle-income countries (LMICs) has led to substantial efforts to improve access to chemotherapy. The present study's objectives were to obtain an overview of the safe handling practices implemented in LMICs' healthcare facilities when dealing with chemotherapy drugs and to prioritize opportunities for improving them. We conducted an online survey, from June 2018 to April 2019, among LMIC healthcare facilities dealing with chemotherapy drugs. Facilities were asked to self-assess their chemotherapy handling processes using Cyto-SAT, a self-assessment tool incorporating 134 items organized into 10 domains (management, personnel, logistics, prescription, preparation, administration, incident management, waste management, cleaning, and patient counselling). Data were recorded on an online platform (www.datapharma.ch/cyto-SAT). The survey enrolled 53 healthcare facilities (15 from low-income, 26 from lower-middle-income, and 12 from upper-middle-income countries). The median level of implementation of safe practices was 63% (Q1:39%-Q3:77%). Facilities in low-income countries (LICs) reported lower median levels of safe practices than middle-income countries (MICs) [LICs: 32% (Q1:24%-Q3:62%), Lower-MICs: 63% (Q1:49%-Q3:70%), Upper-MICs: 85% (Q1:77%-Q3:93%)]. The biggest differences between country categories were observed in the domains related to personnel, preparation processes, and incident management. This overview of practices highlighted a large variability and major gaps in the safe handling of chemotherapy drugs in LMICs. Improvement strategies are needed to increase patient and staff safety and limit environmental contamination, especially in LICs. Safe handling programs should be part of continuing efforts to improve access to quality cancer drugs and should be integrated into national cancer control programs.
Identifiants
pubmed: 33622088
doi: 10.1177/1078155221995539
pmc: PMC8832569
doi:
Substances chimiques
Antineoplastic Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
410-420Références
J Oncol Pharm Pract. 2021 Sep;27(6):1422-1431
pubmed: 32941103
Am J Health Syst Pharm. 2002 Sep 1;59(17):1648-68
pubmed: 12229895
J Oncol Pract. 2016 Dec;12(12):1262-1271
pubmed: 27868581
Environ Health Prev Med. 2020 Apr 13;25(1):11
pubmed: 32284041
Am J Health Syst Pharm. 2018 Dec 15;75(24):1996-2031
pubmed: 30327293
Am J Health Syst Pharm. 2001 Oct 1;58(19):1835-41
pubmed: 11596700
J Oncol Pharm Pract. 2015 Feb;21(1):26-35
pubmed: 25361598
Asian Pac J Cancer Prev. 2013;14(1):69-73
pubmed: 23534806
CA Cancer J Clin. 2006 Nov-Dec;56(6):354-65
pubmed: 17135692
J Oncol Pharm Pract. 2007;13 Suppl:1-81
pubmed: 17933809
Lancet. 1979 Jun 9;1(8128):1250-1
pubmed: 87722
Asian Pac J Cancer Prev. 2004 Apr-Jun;5(2):164-8
pubmed: 15244519